AMF Tjanstepension AB lowered its stake in shares of Humana Inc. (NYSE:HUM – Get Rating) by 17.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,170 shares of the insurance provider’s stock after selling 17,655 shares during the quarter. AMF Tjanstepension AB’s holdings in Humana were worth $36,207,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of HUM. BerganKDV Wealth Management LLC grew its stake in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 62 shares during the period. Riverview Trust Co purchased a new position in shares of Humana during the 1st quarter valued at $32,000. Bank of New Hampshire purchased a new position in shares of Humana during the 1st quarter valued at $36,000. CNB Bank purchased a new position in shares of Humana during the 1st quarter valued at $44,000. Finally, DeDora Capital Inc. purchased a new position in shares of Humana during the 1st quarter valued at $48,000. Institutional investors own 94.93% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on HUM. Deutsche Bank Aktiengesellschaft increased their price objective on Humana from $450.00 to $514.00 in a report on Thursday. Wells Fargo & Company increased their price objective on Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a report on Wednesday, May 25th. StockNews.com raised Humana from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 20th. SVB Leerink reaffirmed a “maintains” rating on shares of Humana in a report on Thursday. Finally, Barclays increased their price objective on Humana from $500.00 to $570.00 and gave the company a “maintains” rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $510.61.
Insider Buying and Selling at Humana
Humana Stock Up 1.0 %
Shares of HUM traded up $4.84 on Thursday, reaching $483.19. The stock had a trading volume of 15,570 shares, compared to its average volume of 1,103,498. The firm has a market capitalization of $61.12 billion, a price-to-earnings ratio of 20.30, a price-to-earnings-growth ratio of 1.42 and a beta of 0.80. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.53 and a current ratio of 1.53. The company has a 50-day simple moving average of $460.24 and a 200-day simple moving average of $438.81. Humana Inc. has a 12-month low of $351.20 and a 12-month high of $497.47.
Humana (NYSE:HUM – Get Rating) last announced its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.67 by $1.00. The business had revenue of $23.66 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.89 earnings per share. Sell-side analysts predict that Humana Inc. will post 24.65 EPS for the current year.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
- C3.AI Stock is a Bargain Enterprise Artificial Intelligence Game Changer
- Two High Yield ETF That Can Substitute For Index Funds
- Did The FOMC Put A Bottom In The S&P 500?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.